Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 926 - 950 of 2,711

«
1
…
36
37
38
39
40
…
109
»

Thrombophilia & Thrombosis in Cancer Patients: Novel Advances

Thrombophilia & Thrombosis in Cancer Patients: Novel Advances

By: Cindy Leissinger, MD

Acquired Inhibitors in Cancer: State-of-the Art Management

Acquired Inhibitors in Cancer: State-of-the Art Management

By: Cindy Leissinger, MD

Acquired Inhibitors in Cancer: State-of-the Art Management

Acquired Inhibitors in Cancer: State-of-the Art Management

By: Cindy Leissinger, MD

Hematology Malignancies Session

Hematology Malignancies Session

By: Javier Pinilla-Ibarz, MD, PhD, Luis E. Fayad, MD, Sergio Giralt, MD, Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

Panel Discussion: Practice Changing Developments in Benign and Malignant Hematology

Panel Discussion: Practice Changing Developments in Benign and Malignant Hematology

By: Joseph Tuscano, MD

Indentification and Management of Tyrosine Kinase Inhibitors (TKIs) Toxicities

Indentification and Management of Tyrosine Kinase Inhibitors (TKIs) Toxicities

By: Josephine Previlon, MPAS, PA-C

New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors

New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors

By: Nicole Ianniello, PharmD

State of the Art Management of Sickle Cell Anemia

State of the Art Management of Sickle Cell Anemia

By: Oyebimpe Adesina, MD

Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions

Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions

By: Rami Komrokji, MD

Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions

Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions

By: Rami Komrokji, MD

Targeted Therapy for B- and T-cell Non-Hodgkin's Lymphomas

Targeted Therapy for B- and T-cell Non-Hodgkin's Lymphomas

By: Eduardo M. Sotomayor, MD

Acute Myeloid and Lymphoid Leukemias

Acute Myeloid and Lymphoid Leukemias

By: Hugo F. Fernandez, MD

Acute Myeloid and Lymphoid Leukemias

Acute Myeloid and Lymphoid Leukemias

By: Hugo F. Fernandez, MD

Targeted Therapy for B- and T-cell Non-Hodgkins Lymphomas

Targeted Therapy for B- and T-cell Non-Hodgkins Lymphomas

By: Eduardo M. Sotomayor, MD

Changing the landscape of treatment in Peripheral T-cell Lymphoma

Changing the landscape of treatment in Peripheral T-cell Lymphoma

By: Luis E. Fayad, MD

Updates in Multiple Myelom

Updates in Multiple Myelom

By: Aaron S. Rosenberg, MD, MS

Updates in CML and CLL

Updates in CML and CLL

By: Alexis M. Cruz Chacon, MD

Immunotherapy in Heme Malignancies

Immunotherapy in Heme Malignancies

By: Arta M. Monjazeb, MD, PhD

New Therapeutic Options in the Myelodysplastic Syndromes

New Therapeutic Options in the Myelodysplastic Syndromes

By: Brian A. Jonas, MD, PhD, FACP

Cancer And Thrombosis

Cancer And Thrombosis

By: Craig S. Kitchens,, MD, MACP

DOACs in Cancer

DOACs in Cancer

By: Craig S. Kitchens,, MD, MACP

B-Cell NHL and Hodgkin’s Disease Biologicals, Checkpoint Inhibitors, CAR-T cells

B-Cell NHL and Hodgkin’s Disease Biologicals, Checkpoint Inhibitors, CAR-T cells

By: Eduardo M. Sotomayor, MD

B-Cell NHL and Hodgkin’s Disease

B-Cell NHL and Hodgkin’s Disease

By: Eduardo M. Sotomayor, MD

CLL & CML (a lot on the first and not much on the second) Part 2

CLL & CML (a lot on the first and not much on the second) Part 2

By: Javier Pinilla-Ibarz, MD, PhD

CLL & CML (a lot on the first and not much on the second) Part 1

CLL & CML (a lot on the first and not much on the second) Part 1

By: Javier Pinilla-Ibarz, MD, PhD

«
1
…
36
37
38
39
40
…
109
»

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok